Plain-English translation of NCT07244328 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Epilepsy research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , an experimental treatment made from special brain cells called GABAergic interneuron progenitor cells. Doctors will inject this treatment directly into a specific part of your brain using a surgical procedure, with the hope that it might reduce your seizures. This is an early-stage study exploring whether this new approach can help people whose epilepsy hasn't responded well to standard medications.
Many people with temporal lobe epilepsy continue to have seizures even after trying multiple anti-seizure drugs, and their options for treatment are limited. This medication represents a completely different approach—rather than just masking seizure activity, it aims to repair the underlying brain damage that may be causing the seizures in the first place.
You likely qualify if…
You likely don't qualify if…
You would undergo brain surgery to receive an injection of the treatment, followed by medications to help your immune system tolerate the new cells. Over the next 2 years, you'll have regular clinic visits, brain imaging scans, and blood tests to monitor your safety and how well the treatment is working. You'll also keep a seizure diary and complete questionnaires about your quality of life, thinking ability, and mood to help doctors understand the full impact of the treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China